Eli Lilly has completed the acquisition of immuno-oncology company ARMO BioSciences in an all-cash deal valued at nearly $1.6bn.
Lilly originally signed a definitive agreement last month to buy all outstanding shares of ARMO for $50 each. The deal is part of Lilly鈥檚 strategy to strengthen its immune-oncology portfolio.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The transaction was carried out by merging Bluegill Acquisition Corporation with ARMO, which has now become a wholly owned subsidiary of Lilly.
Lilly Oncology senior vice-president and president Sue Mahony said: 鈥淲e are pleased to announce the completion of our acquisition of ARMO BioSciences, which adds a promising clinical immunotherapy asset, pegilodecakin, to Lilly鈥檚 oncology portfolio.
鈥淟illy will continue to pursue medicines that use the body鈥檚 immune system in new ways to treat cancer and that have the potential to make a meaningful difference to patients with cancer.鈥�
ARMO is a late-stage immuno-oncology firm working towards the development of new product candidates that will leverage patients鈥� immune system to detect and destroy tumours.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPegilodecakin is the company鈥檚 lead candidate that is currently undergoing Phase III clinical trial for the treatment of patients suffering from pancreatic cancer.
Previously, the PEGylated IL-10 is said to have demonstrated clinical benefit as a monotherapy, as well as in combination with chemotherapy and checkpoint inhibitor therapy, for a variety of tumours.
The drug candidate is also being studied in other clinical trials for different types of solid tumours, including lung cancer, melanoma and renal cell cancer.
As well as from pegilodecakin, ARMO is also developing other immuno-oncology product candidates.
